Tricyclic steroid hormone nuclear receptor modulators

Details Tricyclic steroid hormone nuclear receptor modulators Tricyclic steroid hormone nuclear receptor modulators

2003-06-13

2008-08-12

Saeed, Kamal (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S395000

Reexamination Certificate

active

07411072

ABSTRACT:
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula:or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.

REFERENCES:
patent: 3205264 (1965-09-01), Tristram et al.
patent: 3351588 (1967-11-01), Davis et al.
patent: 3519621 (1970-07-01), Humber et al.
patent: 3859356 (1975-01-01), Houlihan et al.
patent: 4282233 (1981-08-01), Vilani
patent: 4963450 (1990-10-01), Miyazaki et al.
patent: 4999363 (1991-03-01), Oshima et al.
patent: 5024912 (1991-06-01), Neishi et al.
patent: 5093210 (1992-03-01), Ohta et al.
patent: 5151545 (1992-09-01), McCarthy et al.
patent: 5378701 (1995-01-01), Ohshima et al.
patent: 5726325 (1998-03-01), Yoshida et al.
patent: 6289190 (2001-09-01), Amamiya et al.
patent: 6362188 (2002-03-01), Guzi et al.
patent: 2007/0037788 (2007-02-01), Gavardinas et al.
patent: 0 549 352 (2000-03-01), None
patent: 1 001 822 (1965-08-01), None
patent: 1 043 158 (1966-09-01), None
patent: 1 242 096 (1971-08-01), None
patent: 1 501 321 (1978-02-01), None
patent: 01161245 (1989-06-01), None
patent: 02032358 (1990-02-01), None
patent: 02113258 (1990-04-01), None
patent: 04046352 (1992-02-01), None
patent: 05002278 (1993-01-01), None
patent: 05281765 (1993-10-01), None
patent: 09101200 (1997-04-01), None
patent: 2001089680 (2001-04-01), None
patent: WO 97/11071 (1997-03-01), None
patent: WO 99/33786 (1999-07-01), None
patent: WO 00/06137 (2000-02-01), None
patent: WO 00/59884 (2000-10-01), None
patent: WO 01/95892 (2001-12-01), None
patent: WO 02/09759 (2002-02-01), None
patent: WO 02/17895 (2002-03-01), None
patent: WO 02/096893 (2002-12-01), None
Treibs et al., caplus an 1951:8622.
Werner, et al., “Imidazoline derivatives with antiarrhytmic activity,” Journal of Medicinal Chemistry, vol. 10, No. 4, pp. 575-582; XP002283810 (1967).
Gadient, et al., “Uber neuartige tricyclische Thiazepin- und Thiepin-Derivate,” Helvetica Chimica ACTA, vol. 45, No. 6, pp. 1860-1870; XP002283811 (1962).
Villani, et al, “Derivatives of 12, 11-dihydro-5H-dibenzo'a,d!cycloheptene and related compounds. II” Journal of Medicinal Chemistry, vol. 7, No. 4, pp. 457-460; XP002283812 (1964).
Bille-Same, et al., “Fulvenes et ethylenes thermochromes. LXXII. (1) Observations dans la serie du dibenzo'a,d!cyclohepta'1,4!diene,” Bulletin De La Societe Chimique De France, No. 11, pp. 4212-4214; XP002283813 (1972).
Cordi, et al., “Synthesis and structure-activity of 4(5)-(2-2-diphenylethyl)imidazoles as new alpha2-adrenoreceptor agonists,” European Journal of Medicinal Chemistry, vol. 25, No. 7, pp. 557-568; XP002283814 (1990).
Cheng, et al., “Synthesis and structure-activity relationships of 9-substituted acridines as endothelin-A receptor antagonists,” Biorganic & MedicinalChemistry Letters, vol. 6, No. 24, pp. 2999-3002; XP002283815 (1996).
Bastian, et al., “4H-Benzo ‘4,5!cyclohepta’1,2-b!thiophene,” Helvetica Chimica ACTA, vol. 49, pp. 214-234; XP002263672 (1966).
Daich, et al., “On the synthesis and reactivity of 4,10-dihydrobenzo'b!thieno-‘2,3-e!thiepin-10-acetic acid and 5,10-dihydrobenzo e!thieno’2,3-b!thiepin-10-acetic acid,” Journal of Heterocyclic Chemistry, vol. 29, No. 7, pp. 1789-1795; XP002283816 (1992).
Polman, et al., “Photoaddition of aromatic ketones to some arylacetylenes; formation of alpha,beta-unsaturated ketones and aldehyde,” Recueil Des Travaux Chimiques Des Pays-Bas, vol. 92, pp. 845-854; XP008031504 (1973).
Wittig, et al., “Uber Ringerweiterung und Ringverengerung auf der Basis von Ylidisomerisationen,” Justus Liebigs Annalen Der Chemie, vol. 594, pp. 89-118; XP008031512 (1955).
Davis, et al., “New psychotropic agents. VIII. Analogues of amitriptyline containing the normeperidine group,” Journal of Medicinal Chemistry, vol. 10, No. 4, pp. 627-635; XP002284192 (1967).
R. G. Micetich, “Lithiation of five-membered heteroaromatic compounds. The methyl substitued 1,2-azoles, oxadiazoles, and thiadiazoles,” Canadian Journal of Chemistry, vol. 48, No. 13, pp. 2006-2015 (1970).
Bergmann, et al., “Fulvenes and Thermochromic Ethylenes. Part 57. The Wittig-Horner Reaction with Fulvene Ketones and Related Ketones,” Synthesis, vol. 2, No. 4, pp. 183-189 (1970).
Fox, et al., “Synthetic Antigonadotropines. II,” J. Med. Chem, vol. 7, No. 6, pp. 790-792 (1964).
Boris, et al., “Antigonadotrophic Activity of Some Substituted Triphenylethlene Derivatives,” Arch. Intern. Pharmacodyn, vol. 151, No. 3-4, pp. 475-489 (1964).
Bergmann, et al., “Fulvenes and Thermochromic Ethylenes. XXXIII. Polycyclic Derivataives of Heptafulvene,” J. Org. Chem, vol. 28, No. 12, pp. 3341-3343 (1963).
Rabinovitz, J. Chem. Soc., Perkin Transactions 2: Physical Organic Chemistry, vol. 12, pp. 1836-1838 (1972).

Affiliated with

Also associated with

Rating

Tricyclic steroid hormone nuclear receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tricyclic steroid hormone nuclear receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic steroid hormone nuclear receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4013780